In last trading session, Spyre Therapeutics Inc (NASDAQ:SYRE) saw 0.33 million shares changing hands with its beta currently measuring 2.82. Company’s recent per share price level of $16.29 trading at -$0.6 or -3.55% at ring of the bell on the day assigns it a market valuation of $983.16M. That closing price of SYRE’s stock is at a discount of -147.15% from its 52-week high price of $40.26 and is indicating a premium of 33.03% from its 52-week low price of $10.91. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.57 million shares which gives us an average trading volume of 562.81K if we extend that period to 3-months.
For Spyre Therapeutics Inc (SYRE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.23. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Spyre Therapeutics Inc’s shares saw a change of -47.37% in year-to-date performance and have moved 3.82% in past 5-day. Spyre Therapeutics Inc (NASDAQ:SYRE) showed a performance of 7.31% in past 30-days. Number of shares sold short was 12.59 million shares which calculate 26.96 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 45 to the stock, which implies a rise of 63.8% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 71. It follows that stock’s current price would drop -145.55% in reaching the projected high whereas dropping to the targeted low would mean a loss of -145.55% for stock’s current value.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 2.86% while estimates for its earnings growth in next 5 years are of -1.28%.
Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders
Insiders are in possession of 8.71% of company’s total shares while institution are holding 106.07 percent of that, with stock having share float percentage of 116.19%. Investors also watch the number of corporate investors in a company very closely, which is 106.07% institutions for Spyre Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at SYRE for having 7.51 million shares of worth $176.51 million. And as of 2024-06-30, it was holding 16.568 of the company’s outstanding shares.
The second largest institutional holder is FAIRMOUNT FUNDS MANAGEMENT LLC, which was holding about 4.02 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8668 of outstanding shares, having a total worth of $94.47 million.
On the other hand, SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.74 shares of worth $44.69 million or 4.55% of the total outstanding shares. The later fund manager was in possession of 1.66 shares on Mar 31, 2025 , making its stake of worth around $27.05 million in the company or a holder of 2.75% of company’s stock.
